07:00 , Oct 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: NAD(P) dependent steroid dehydrogenase-like (NSDHL); K-Ras (KRAS)

Cancer INDICATION: Cancer Cell culture and mouse studies suggest inhibiting NSDHL could help treat mutant KRAS-driven cancer. In a transgenic mouse fibroblast cell line expressing an oncogenic mutation of human KRAS, NSDHL knockout decreased proliferation compared with...